Hepatocellular Carcinoma (HCC)

TARGET-HCC

HCC is a major health problem worldwide and, although we have made progress in preventing it, treatment of HCC is just getting started. TARGET-HCC collects real world data on HCC treatment at academic sites, in clinical practice, through the US and in Europe. TARGET-HCC is an important tool for tracking our progress towards complete control of HCC. Adrian Di Bisceglie, MD

While there has been significant progress in hepatocellular carcinoma research, HCC continues to be the most common type of primary liver cancer creating a large need for real-world data and insights to battle the disease. 

The TARGET-HCC study collects real-world data to enhance the understandings of HCC's natural history and management in real-world settings, which is provided to our partners to inform drug development solutions. TARGET-HCC also has a biorepository linked to validated clinical outcomes, including patient reported outcomes, which gives partners better ways to achieve improved clinical outcomes and better care for patients.

study goals:

  • Understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice
  • Evaluate the impact of HCC treatment interventions and concomitant medications on co-morbid conditions and liver function
  • Evaluate patient-reported outcomes measured during the natural course and management of HCC

Launched:

September 2016

 

enrollment goal:

5,000

TARGET-HCC Steering Committee

Adrian Di Bisceglie, MD (Co-Chair)
Chief of Hepatology and University Liver Center Co-Director, St. Louis, MO

Anthony El-Khoueiry, MD (Co-Chair)
Associate Professor of Clinical Medicine, Los Angeles, CA

Roniel Cabrera, MD, MS (Protocol Author)
Director & Associate Professor of Medicine, Gainesville, FL

Michael W. Fried, MD (Scientific Advisor)  
Professor of Medicine and UNC Liver Center Director, Chapel Hill, NC

David Nelson, MD (Scientific Advisor)
Senior VP of Health Affairs and UF Health President, Gainesville, FL

Bruno Sangro, MD 
Director of the Liver Unit and Professor of Internal Medicine, Navarra, Spain

R. Kate (Katie) Kelley, MD 
Associate Professor of Clinical Medicine, San Francisco, CA

Massimo Colombo, MD 
Director of the Center for Translational Research in Liver Disease, Rozzano, Italy

Tim Meyer, MD 
Professor of Experimental Cancer Medicine, London, UK

Pippa Newell, MD
Clinical Research Scientist, Portland, OR